Skip to content

Explore Grants

Recipient Purpose Term Amount
Brigham & Women's Hospital, Inc. To support the Program On Regulation, Therapeutics, and Law, which will evaluate the impact of drug innovation incentive policies. 2016 - 2017 $742,905
Brigham & Women's Hospital, Inc. To evaluate the impact of Pharmacy Benefits Managers on prescription drug pricing. 2017 - 2018 $77,315
Brigham & Women's Hospital, Inc. To support the Program On Regulation, Therapeutics, And Law. 2017 - 2020 $3,268,850
Center for Health Policy Development To support a working group of state health policy experts and stakeholders to examine emerging strategies for addressing the high cost of prescription drugs. 2016 - 2017 $146,271
Center for Health Policy Development To support the launch of the Center for Prescription Drug Price Action. 2017 - 2019 $2,021,350
Civica, Inc. To promote availability and affordability of essential generic drugs. 2018 - 2023 $1,000,000
Civica, Inc.** To promote availability and affordability of essential generic drugs. 2018 - 2030 $9,000,000
Evidence for Healthcare Improvement To produce Institute for Clinical and Economic Review reports on new drugs that include information about a drug's comparative effectiveness, cost effectiveness, and potential budget impact. 2015 - 2017 $5,232,002
Evidence for Healthcare Improvement To support the Institute for Clinical and Economic Review research that provides independent analyses of the comparative cost effectiveness for newly-introduced pharmaceutical drugs. 2017 - 2020 $13,966,892
George Mason University Foundation, Inc. To develop and disseminate policy options related to the negotiation of prescription drug prices by Medicare. 2018 $37,475
Henry J. Kaiser Family Foundation To examine trends in prescription drug prices and Medicare Part D formulary coverage and broadly disseminate the findings policy briefs, papers, and convenings. 2018 - 2020 $484,587
Henry J. Kaiser Family Foundation To support Kaiser Health News in providing independent reporting on pharmaceutical drug development and pricing. 2016 - 2018 $1,060,500
Henry J. Kaiser Family Foundation To support Kaiser Health News in providing independent reporting on pharmaceutical drug development and pricing. 2017 - 2018 $200,000
Initiative for Medicines, Access, & Knowledge, Inc. To produce a report that will outline strategies to address pharmaceutical patents and pricing structures. 2016 $209,500
Initiative for Medicines, Access, & Knowledge, Inc. To support efforts to provide patients with affordable access to life-saving medications and improve public health. 2017 - 2019 $3,958,828
Johns Hopkins University To promote the adoption of a waste-free prescription drug formulary by private corporations in place of the current drug rebate system. 2018 - 2021 $940,607
Johns Hopkins University To increase the availability and affordability of life-saving drugs while maintaining incentives for innovation in drug development. 2015 - 2017 $318,000
Johns Hopkins University To develop research on policy options that maximize access to and affordability of prescription drugs. 2016 - 2019 $3,586,034
Kaiser Foundation Health Plan of Washington To evaluate a program designed to improve the value of pharmaceutical care. 2018 - 2021 $503,919
Maryland Citizens Health Initiative Education Fund, Inc. To educate the public about a recently enacted law that prohibits price gouging in the sale of essential generic medications, along with other efforts states can take to impact rising drug costs. 2017 - 2018 $400,000
Memorial Sloan-Kettering Cancer Center To build a program that communicates evidence-based methodologies for drug pricing and payment. 2015 - 2019 $4,394,354
National Academy of Sciences To support an Institute of Medicine research project that will study patient access to effective and affordable therapies. 2016 - 2018 $749,161
National Academy of Sciences To host a workshop examining the role of the National Institutes of Health in prescription drug innovation in order increase patient access to products derived in part from federal research. 2018 - 2020 $254,960
National Conference of State Legislatures To provide stakeholders with educational resources to support evidence-based decision making related to prescription drug pricing. 2017 - 2019 $264,427
Arnold A decorative icon